Sitemap
- Home
- Dermatology
- Respiratory
- Cardiology
- Dyslipidaemia
- Articles
- Praluent® (alirocumab) mechanism of action
- Cardiovascular outcomes for diabetes patients Praluent® (alirocumab)
- ODYSSEY OUTCOMES Efficacy Praluent® (alirocumab)
- FH I & FH II Studies Praluent® (alirocumab)
- ODYSSEY OUTCOMES Safety Profile Praluent® (alirocumab)
- Therapeutic indications for Praluent® (alirocumab)
- NICE and SMC Guidance Praluent® (alirocumab)
- Dosing options – customise your patient’s treatment with Praluent® (alirocumab)
- ODYSSEY OUTCOMES Trial Design Praluent® (alirocumab)
- Praluent® (alirocumab) Administration
- Specific characteristics of Praluent® (alirocumab)
- Unmet Needs in Dyslipidaemia
- Resources
- Education
- Articles
- Dyslipidaemia
- Other Topics
- Rare Disease
- Pompe
- Better Care for Rare
- Gaucher
- Articles
- Gaucher Mechanism of Disease
- Signs and Symptoms of Gaucher disease
- Gaucher Biochemistry Diagnosis support
- Differentiating Gaucher disease subtypes
- Gaucher disease Management and Specialist Treatment Centres
- Diagnosis of Gaucher disease
- Gaucher Neurology Diagnosis support
- Epidemiology of Gaucher disease
- Gaucher Haematology Diagnosis support
- Articles
- Fabry
- Vaccines
- Diabetes
- Type 1 Diabetes
- Articles
- T1 Evidence in Children
- T1 Evidence in Adults
- Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM
- T1DM - Meta-Analysis
- Toujeo (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T1DM
- T1 Edition Junior Study
- Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM
- InRange Study
- SPARTA study
- Resources
- Articles
- Type 2 Diabetes
- Articles
- Video: BRIGHT study
- ORION Observational Study
- Hospitalisation rates with basal insulin in adults with T2D
- Benefits of switching to Toujeo (insulin glargine 300 Units/mL) through patient case studies and patient reported outcomes
- Explore Toujeo (insulin glargine 300 Units/mL) data from the pivotal randomised controlled clinical trials
- Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D
- Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA
- Treatment persistence with basal insulin in adults with T2D
- Toujeo (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T2DM
- Head to Head Studies
- Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T2DM
- Events
- Education
- Diabetes UK 2024: Connecting the Dots: Benefits of pen connectivity for people living with diabetes
- Paradigm 2024: Ketan Dhatariya
- Paradigm 2024: Lesley Mills
- Diabetes UK 2024: Navigating Hyperglycaemia after GLP-1s with Insulin
- Diabetes UK 2025: Managing the Cardiometabolic Patient – All in it together
- Diabetes UK 2024: Sustainably scripting tomorrow with Sanofi's Planet Cares Programme and Pen Recycling pilot
- Paradigm 2024: Anne Goodchild
- Paradigm 2024: Saqib Mahmud
- Articles
- Type 1 Diabetes
- Transplant
- Transplant
- Articles
- Education
- Patient Case Study Presentations - EBMT 2025
- EBMT 2024: The late effects of chronic GvHD: The challenge of long-term management
- EBMT 2024: QoL and chronic GvHD
- EBMT 2024: Treatment of steroid refractory chronic GvHD
- InTen Nurse Forum - ACCEND Framework
- EBMT 2024: Frontline treatment of chronic GvHD
- InTen Nurse Forum: What is chronic GvHD?
- Patient Case Study 8: Treatment of Severe cGVHD
- Patient Case Study 9: Treatment of cGVHD with Steroid-related Complications
- EBMT 2024: Roundtable: Exploring clinical cases
- EBMT 2024: Expanding the cGvHD treatment paradigm with novel therapeutics
- EBMT 2024: Advances in the biology of chronic GvHD
- EBMT 2024: Pulmonary chronic GvHD: The need for early identification and improved management
- Transplant
- Oncology
- Neurology
- Products
- Avaxim®
- Cerdelga®▼(Eliglustat)
- Efluelda TIV-HD▼
- Supemtek TIVr▼
- Vaxigrip Trivalent Influenza Vaccine
- Cablivi®
- Avaxim® Junior hepatitis A vaccine (inactivated, adsorbed)
- Praluent®
- Beyfortus®▼ (nirsevimab)
- Myozyme®
- Repevax®
- Revaxis®
- Cerezyme®
- REZUROCK®▼
- Lantus®
- Verorab®
- Toujeo®
- Trurapi®▼
- Typhim Vi (Typhoid Polysaccharide Vaccine)®
- SARCLISA® (isatuximab) RRMM
- Fabrazyme®
- MenQuadfi
- Dupixent® (dupilumab) Atopic Dermatitis
- Stamaril® (Yellow Fever Vaccine Live)
- DUPIXENT® (dupilumab) Severe Asthma
- SARCLISA® (isatuximab) Ti NDMM
- Nexviadyme® ▼
- Aldurazyme®
- Dupixent® (dupilumab) Prurigo Nodularis
- Therapeutic Areas
- Sitemap
- Sign Up
- Sign In
- Terms of Use
- Privacy Policy
- Cookie Policy